On October 21, 2021 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, reported that Derek Jantz, Ph.D., Chief Scientific Officer and Co-Founder, will present at the Jefferies Virtual Gene Therapy/Gene Editing Summit, being held October 27-28, 2021 (Press release, Precision Biosciences, OCT 21, 2021, View Source [SID1234591694]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details for the fireside chat are below:
Jefferies Virtual Gene Therapy/Gene Editing Summit
Date: Wednesday, October 27, 2021
Time: 1:30 to 1:55 ET PM
The Company expects to report that a balance of cash and cash equivalents is approximately $160.5 million as of September 30, 2021. The Company continues to expect that existing cash and cash equivalents will be sufficient to fund planned operations into 2023.
A live webcast of the fireside chat will be accessible on the Company’s website in the Investors section under Events & Presentations: View Source An archived replay of the webcast will be available for approximately 30 days.